title: Utility of FDG-PET/CT in the follow-up of neuroblastoma which became MIBG-negative.
abstract: We report on the case of a 10-month-old female infant with a metastatic neuroblastoma which became MIBG-negative at time of relapse. We discuss the different hypothesis associated with this particular outcome, and the potential utility of FDG-PET as an alternative to follow up the residual disease at this stage.
authors.affiliation: Department of Nuclear Medicine, University Hospital Centre, Timone, Marseille, France. cecile.colavolpe@ap-hm.fr
authors.forename: Cécile
authors.initials: C
authors.lastname: Colavolpe
authors.forename: Eric
authors.initials: E
authors.lastname: Guedj
authors.forename: Serge
authors.initials: S
authors.lastname: Cammilleri
authors.forename: David
authors.initials: D
authors.lastname: Taïeb
authors.forename: Olivier
authors.initials: O
authors.lastname: Mundler
authors.forename: Carole
authors.initials: C
authors.lastname: Coze
mesh_terms: D019797:3-Iodobenzylguanidine / Q000378:metabolism*; D005260:Female; D019788:Fluorodeoxyglucose F18 / Q000378:metabolism; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000473:pathology; D018365:Neoplasm, Residual / Q000000981:diagnostic imaging / Q000473:pathology; D009447:Neuroblastoma / Q000000981:diagnostic imaging* / Q000556:secondary; D049268:Positron-Emission Tomography; D011379:Prognosis; D019275:Radiopharmaceuticals; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; D019797:3-Iodobenzylguanidine